CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vaccine trial aims to shrink throat tumors before surgery
Disease control CompletedThis study tested whether a vaccine called PDS0101, given alone or with an immunotherapy drug (pembrolizumab), could help shrink tumors in patients with HPV-linked throat cancer before they had surgery. The goal was to see if this approach could make the tumors smaller, potential…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Immunotherapy vs. standard care: a Head-to-Head cancer trial
Disease control CompletedThis trial tested if adding a newer immunotherapy drug (durvalumab) to radiation therapy works better than the standard combination of radiation with an older drug (cetuximab). It was for patients with advanced head and neck cancer who could not safely take the usual chemotherapy…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC